RNAi-mediated TCR Knockdown Prevents Autoimmunity in Mice Caused by Mixed TCR Dimers Following TCR Gene Transfer

Molecular Therapy

Volumn 22, Issue 11, 2014, Pages 1983-1991

  Bunse, Mario ^a,b   Bendle, Gavin M ^c,d   Linnemann, Carsten ^c   Bies, Laura ^c   Schulz, Stephan ^e   Schumacher, Ton N ^c   Uckert, Wolfgang ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e Institute of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HETERODIMER; MICRORNA; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ALPHA CHAIN; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; BETA CHAIN; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DIMERIZATION; GENE EXPRESSION; GENE SILENCING; GRAFT VERSUS HOST REACTION; HETERODIMERIZATION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; RNA INTERFERENCE; SURFACE PROPERTY; TCR GENE; VIRAL GENE DELIVERY SYSTEM; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DISEASE MODEL; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; GRAFT VS HOST DISEASE; IMMUNOLOGY; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; SECONDARY; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNITY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; GRAFT VS HOST DISEASE; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; RECEPTORS, ANTIGEN, T-CELL; RNA INTERFERENCE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 84964314498     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.142     Document Type: Article

References (47)

1. Clay, TM, Custer, MC, Sachs, J, Hwu, P, Rosenberg, SA and Nishimura, MI (1999). Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 163: 507-513.
2. Cooper, LJ, Kalos, M, Lewinsohn, DA, Riddell, SR and Greenberg, PD (2000). Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 74: 8207-8212.
3. Fujio, K, Misaki, Y, Setoguchi, K, Morita, S, Kawahata, K, Kato, I et al. (2000). Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. J Immunol 165: 528-532.
4. Kessels, HW, Wolkers, MC, van den Boom, MD, van der Valk, MA and Schumacher, TN (2001). Immunotherapy through TCR gene transfer. Nat Immunol 2: 957-961.
5. de Witte, MA, Coccoris, M, Wolkers, MC, van den Boom, MD, Mesman, EM, Song, JY et al. (2006). Targeting self-antigens through allogeneic TCR gene transfer. Blood 108: 870-877.
6. Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
7. Johnson, LA, Morgan, RA, Dudley, ME, Cassard, L, Yang, JC, Hughes, MS et al. (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
8. Robbins, PF, Morgan, RA, Feldman, SA, Yang, JC, Sherry, RM, Dudley, ME et al. (2011). Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29: 917-924.
9. Parkhurst, MR, Yang, JC, Langan, RC, Dudley, ME, Nathan, DA, Feldman, SA et al. (2011). T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19: 620-626.
10. Morgan, RA, Chinnasamy, N, Abate-Daga, D, Gros, A, Robbins, PF, Zheng, Z et al. (2013). Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36: 133-151.
11. Schumacher, TN (2002). T-cell-receptor gene therapy. Nat Rev Immunol 2: 512-519.
12. van Loenen, MM, de Boer, R, Amir, AL, Hagedoorn, RS, Volbeda, GL, Willemze, R et al. (2010). Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci USA 107: 10972-10977.
13. Bendle, GM, Linnemann, C, Hooijkaas, AI, Bies, L, de Witte, MA, Jorritsma, A et al. (2010). Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 16: 565-70, 1p following 570.
14. Saito, T, Sussman, JL, Ashwell, JD and Germain, RN (1989). Marked differences in the efficiency of expression of distinct alpha beta T cell receptor heterodimers. J Immunol 143: 3379-3384.
15. Sommermeyer, D, Neudorfer, J, Weinhold, M, Leisegang, M, Engels, B, Noessner, E et al. (2006). Designer T cells by T cell receptor replacement. Eur J Immunol 36: 3052-3059.
16. Heemskerk, MH, Hagedoorn, RS, van der Hoorn, MA, van der Veken, LT, Hoogeboom, M, Kester, MG et al. (2007). Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 109: 235-243.
17. Engels, B, Cam, H, Schüler, T, Indraccolo, S, Gladow, M, Baum, C et al. (2003). Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther 14: 1155-1168.
18. Szymczak, AL, Workman, CJ, Wang, Y, Vignali, KM, Dilioglou, S, Vanin, EF et al. (2004). Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22: 589-594.
19. Scholten, KB, Kramer, D, Kueter, EW, Graf, M, Schoedl, T, Meijer, CJ et al. (2006). Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 119: 135-145.
20. Cohen, CJ, Zhao, Y, Zheng, Z, Rosenberg, SA and Morgan, RA (2006). Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 66: 8878-8886.
21. Voss, RH, Kuball, J, Engel, R, Guillaume, P, Romero, P, Huber, C et al. (2006). Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigenspecific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. Immunol Res 34: 67-87.
22. Kuball, J, Dossett, ML, Wolfl, M, Ho, WY, Voss, RH, Fowler, C et al. (2007). Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109: 2331-2338.
23. Cohen, CJ, Li, YF, El-Gamil, M, Robbins, PF, Rosenberg, SA and Morgan, RA (2007). Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 67: 3898-3903.
24. Sommermeyer, D and Uckert, W (2010). Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J Immunol 184: 6223-6231.
25. Bialer, G, Horovitz-Fried, M, Ya'acobi, S, Morgan, RA and Cohen, CJ (2010). Selected murine residues endow human TCR with enhanced tumor recognition. J Immunol 184: 6232-6241.
26. Provasi, E, Genovese, P, Lombardo, A, Magnani, Z, Liu, PQ, Reik, A et al. (2012). Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 18: 807-815.
27. Okamoto, S, Mineno, J, Ikeda, H, Fujiwara, H, Yasukawa, M, Shiku, H et al. (2009). Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res 69: 9003-9011.
28. Ochi, T, Fujiwara, H, Okamoto, S, An, J, Nagai, K, Shirakata, T et al. (2011). Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood 118: 1495-1503.
29. Okamoto, S, Amaishi, Y, Goto, Y, Ikeda, H, Fujiwara, H, Kuzushima, K et al. (2012). A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression. Mol Ther Nucleic Acids 1: e63.
30. Reuß, S, Sebestyén, Z, Heinz, N, Loew, R, Baum, C, Debets, R et al. (2014). TCRengineered T cells: a model of inducible TCR expression to dissect the interrelationship between two TCRs. Eur J Immunol 44: 265-274.
31. Chung, KH, Hart, CC, Al-Bassam, S, Avery, A, Taylor, J, Patel, PD et al. (2006). Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res 34: e53.
32. Saetrom, P, Snøve, O, Nedland, M, Grünfeld, TB, Lin, Y, Bass, MB et al. (2006). Conserved microRNA characteristics in mammals. Oligonucleotides 16: 115-144.
33. Pircher, H, Michalopoulos, EE, Iwamoto, A, Ohashi, PS, Baenziger, J, Hengartner, H et al. (1987). Molecular analysis of the antigen receptor of virus-specific cytotoxic T cells and identification of a new V alpha family. Eur J Immunol 17: 1843-1846.
34. Staveley-O'Carroll, K, Schell, TD, Jimenez, M, Mylin, LM, Tevethia, MJ, Schoenberger, SP et al. (2003). In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol 171: 697-707.
35. Jackson, AL, Bartz, SR, Schelter, J, Kobayashi, SV, Burchard, J, Mao, M et al. (2003). Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21: 635-637.
36. Grimm, D, Streetz, KL, Jopling, CL, Storm, TA, Pandey, K, Davis, CR et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541.
37. Stärck, L, Popp, K, Pircher, H and Uckert, W (2014). Immunotherapy with TCRredirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell-derived T cells. J Immunol 192: 206-213.
38. Lassus, P, Rodriguez, J and Lazebnik, Y (2002). Confirming specificity of RNAi in mammalian cells. Sci STKE 2002: pl13.
39. Pomerantz, JL, Denny, EM and Baltimore, D (2002). CARD11 mediates factor-specific activation of NF-kappaB by the T cell receptor complex. EMBO J 21: 5184-5194.
40. Kim, DH and Rossi, JJ (2003). Coupling of RNAi-mediated target downregulation with gene replacement. Antisense Nucleic Acid Drug Dev 13: 151-155.
41. Du, G, Yonekubo, J, Zeng, Y, Osisami, M and Frohman, MA (2006). Design of expression vectors for RNA interference based on miRNAs and RNA splicing. FEBS J 273: 5421-5427.
42. Rosenberg, SA (2010). Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol Ther 18: 1744-1745.
43. Yuan, B, Latek, R, Hossbach, M, Tuschl, T and Lewitter, F (2004). siRNA Selection Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res 32(Web Server issue): W130-W134.
44. Lu, ZJ and Mathews, DH (2008). Efficient siRNA selection using hybridization thermodynamics. Nucleic Acids Res 36: 640-647.
45. Leisegang, M, Engels, B, Meyerhuber, P, Kieback, E, Sommermeyer, D, Xue, SA et al. (2008). Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med (Berl) 86: 573-583.
46. Morita, S, Kojima, T and Kitamura, T (2000). Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 7: 1063-1066.
47. Prévost-Blondel, A, Zimmermann, C, Stemmer, C, Kulmburg, P, Rosenthal, FM and Pircher, H (1998). Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol 161: 2187-2194.